AI: The Next Revolution In Medicine?

Jan 23, 2019

AI: The Next Revolution In Medicine?

Tagged:

Watch our CEO, Joanna Shields, as she takes the stage and returns to DLD 2019 - an event which is a source of great inspiration and hope.

Given the state of the world today, at BenevolentAI we think we could all benefit from a giant dose of optimism. We believe that unconventional thinking combined with purposeful technology can truly change outcomes in the world. And that is what Joanna touches upon during her talk to the audience at DLD.

More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health

Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.

Jan 26, 2023

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis

BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.

Dec 21, 2022

BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference

BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.

Dec 1, 2022

FAIR Data Foundation: An Enabler for AI Drug Discovery

Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.

Nov 8, 2022

BenevolentAI to present at Jefferies Investor Conference in November

BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.

Nov 4, 2022

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca

Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.

Oct 6, 2022